Promising Combinatorial Therapeutic Strategies Against Non-Small Cell Lung Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 27

PMID 38927911

Authors

Prabhjot Kaur

Santosh Kumar Singh

Manoj K Mishra

Shailesh Singh

Rajesh Singh

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) presents a complex and diverse disease, exhibiting variations at individuals' cellular and histological levels. This complexity gives rise to different subtypes and genetic mutations, posing challenges for accurate diagnosis and effective treatment. Nevertheless, continuous progress in medical research and therapies is continually shaping the landscape of NSCLC diagnosis and management. The treatment of NSCLC has undergone significant advancements in recent years, especially with the emergence of targeted therapies that have shown remarkable efficacy in patients with actionable mutations. This has ushered in the era of personalized medicine in NSCLC treatment, with improvements in molecular and immunohistochemical techniques contributing to enhanced progression-free survival. This review focuses on the latest progress, challenges, and future directions in developing targeted therapies for NSCLC, including tyrosine kinase inhibitors (TKIs), DNA-damaging agents, immunotherapy regimens, natural drug therapy, and nanobodies. Furthermore, recent randomized studies have demonstrated enhanced overall survival in patients receiving different targeted and natural drug therapies.

Citing Articles

Nanotechnology for boosting ovarian cancer immunotherapy.

Kaur P, Singh S, Mishra M, Singh S, Singh R J Ovarian Res. 2024; 17(1):202.

PMID: 39402681 PMC: 11475952. DOI: 10.1186/s13048-024-01507-z.

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.

Garg P, Singhal S, Kulkarni P, Horne D, Malhotra J, Salgia R J Clin Med. 2024; 13(14).

PMID: 39064229 PMC: 11278207. DOI: 10.3390/jcm13144189.

References

Mok T, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22):2244-2250. DOI: 10.1200/JCO.2018.78.7994. View

Cho B, Lee J, Wu Y, Cicin I, Cobo Dols M, Ahn M . Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023; 18(12):1731-1742. DOI: 10.1016/j.jtho.2023.08.018. View

Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M . Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol. 2015; 10(3):486-91. DOI: 10.1097/JTO.0000000000000434. View

Hu X, Feng J, Pham T, Ma H, Ma M, Song R . Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer. Phytomedicine. 2018; 50:88-98. DOI: 10.1016/j.phymed.2018.09.012. View

Shi Y, Zhao Y, Yang S, Zhou J, Zhang L, Chen G . Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. J Thorac Oncol. 2022; 17(5):708-717. DOI: 10.1016/j.jtho.2022.01.015. View

Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H . Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. Cancer Sci. 2019; 111(2):561-570. PMC: 7004511. DOI: 10.1111/cas.14260. View

Zhang F, Guo W, Zhou B, Wang S, Li N, Qiu B . Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2022; 17(7):909-920. DOI: 10.1016/j.jtho.2022.04.012. View

Gendarme S, Bylicki O, Chouaid C, Guisier F . Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Curr Oncol. 2022; 29(2):641-658. PMC: 8870726. DOI: 10.3390/curroncol29020057. View

Miyawaki E, Murakami H, Mori K, Mamesaya N, Kawamura T, Kobayashi H . PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. Jpn J Clin Oncol. 2020; 50(5):617-622. DOI: 10.1093/jjco/hyaa033. View

10.

Choudhury N, Schneider J, Patil T, Zhu V, Goldman D, Yang S . Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic -Rearranged Lung Cancers. JTO Clin Res Rep. 2021; 2(7):100187. PMC: 8474494. DOI: 10.1016/j.jtocrr.2021.100187. View

11.

Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin S . PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int J Cancer. 2018; 144(5):1092-1103. PMC: 6320711. DOI: 10.1002/ijc.31770. View

12.

Wang J, Chi Y, Chen H, Jia B, Zhai X, Ma M . [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer  Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience]. Zhongguo Fei Ai Za Zhi. 2022; 25(7):493-500. PMC: 9346162. DOI: 10.3779/j.issn.1009-3419.2022.102.26. View

13.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

14.

Deben C, Lardon F, Wouters A, Op de Beeck K, Van den Bossche J, Jacobs J . APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Lett. 2016; 375(2):313-322. DOI: 10.1016/j.canlet.2016.03.017. View

15.

Dziadziuszko R, Krebs M, De Braud F, Siena S, Drilon A, Doebele R . Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021; 39(11):1253-1263. PMC: 8078299. DOI: 10.1200/JCO.20.03025. View

16.

Pham T, Jayasinghe M, Pham T, Yang Y, Wei L, Usman W . Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021; 10(4):e12057. PMC: 7886705. DOI: 10.1002/jev2.12057. View

17.

Lee A, Yuan Y, Eccles L, Chitkara A, Dalen J, Varol N . Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. Cancer Treat Res Commun. 2022; 33:100648. DOI: 10.1016/j.ctarc.2022.100648. View

18.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

19.

Datar I, Sanmamed M, Wang J, Henick B, Choi J, Badri T . Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res. 2019; 25(15):4663-4673. PMC: 7444693. DOI: 10.1158/1078-0432.CCR-18-4142. View

20.

Melosky B, Kambartel K, Hantschel M, Bennetts M, Nickens D, Brinkmann J . Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Mol Diagn Ther. 2021; 26(1):7-18. PMC: 8766385. DOI: 10.1007/s40291-021-00563-1. View